SCHEMBL328960

SCHEMBL328960

CCCC(O)C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
TDP1 Q9NUW8 3/20 0.49
MAPK1 P28482 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49
LTA4H P09960 1/20 0.47
LAP3 P28838 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CTSK P43235 1/20 0.46
LMNA P02545 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45
CTSL P07711 1/20 0.44
CTSS P25774 1/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16979053 1.00 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL6869938 0.90 ALDH1A1 (0.54) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL30759387 0.90 ALDH1A1 (0.54) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL16648567 0.89 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL16648564 0.89 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL3736932 0.87 CETP (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL7305728 0.87 CETP (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL21245794 0.87 CETP (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL7305733 0.87 CETP (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4
SCHEMBL2677628 0.87 CETP (0.52) ALDH1A1TDP1MAPK1L3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353872-A1 Ligand-Modified Oligonucleotides NOVO NORDISK A/S (DK) 2025-11-20 US disclosed
WO-2025137231-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
EP-2407447-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2018-04-18 EP disclosed
US-8552215-B2 Method for producing optically active 2-hydroxy ester and novel intermediate compound TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2013-10-08 US disclosed
EP-2407447-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND Tokyo University Of Science Educational Foundation Administrative Organization (JP) 2012-01-18 EP disclosed
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2011-12-29 US disclosed
US-6927290-B2 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-09 US disclosed
EP-1160236-B1 Production of mixed acid anhydride and amine compound SUMITOMO CHEMICAL CO (JP) 2005-05-25 EP disclosed
US-20040210059-A1 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed
US-6753431-B2 REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2004-06-22 US disclosed
US-20020032346-A1 Production of mixed acid anhydride and amide compound SUMITOMO CHEMICAL CO., LTD. 2002-03-14 US disclosed
EP-1160236-A2 Production of mixed acid anhydride and amine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-05 EP disclosed
US-5610153-A ENZYME INHIBITORS; TREATMENT OF VASCULAR PROLIFERATION DISORDERS, STERILITY DYSFUNCTION, DYSMENORRHEA CIBA-GEIGY CORPORATION (US) 1997-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353872-A1 Ligand-Modified Oligonucleotides NCL, ADAR, NSUN3 ALDH1A1 3893/4885TDP1 953/4885MAPK1 4534/4885
US-20040210059-A1 Production of mixed acid anhydride and amide compound CA2, CA1, CA3 ALDH1A1 543/4885TDP1 3414/4885MAPK1 1266/4885
US-20020032346-A1 Production of mixed acid anhydride and amide compound CA2, CA1, CA3 ALDH1A1 543/4885TDP1 3414/4885MAPK1 1266/4885
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND CA7, HAO2, HACL2 ALDH1A1 239/4885TDP1 4097/4885MAPK1 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.